Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2015-004347-39Phase 3Completed
Phase 3, randomised, double-blind trial of lemborexant in Insomnia (4 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Change from baseline in mean latency to persistent sleep on Days 29 and 30. Started Aug 2016; status: completed.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2015-004347-39.